Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Schisanalactone A is a naturally occurring triterpenoid isolated from the Vietnamese mushroom *Ganoderma colossum*. It belongs to the colossolactone family of compounds, which are characterized by the presence of a six-membered lactone ring (ring D) and, in some cases, a seven-membered lactone ring (ring A). Research presented at AACR 2017 highlighted its potential chemotherapeutic effects, demonstrating cytotoxic activity against several solid tumor cell lines, including breast (MCF-7), cervical (HeLa), colorectal (HCT-116), and liver (HepG2) cancer cells. In these studies, schisanalactone A exhibited IC50 values ranging from 4.9 to 64.2 µM. Additionally, the compound has shown weak antioxidant activity in DPPH free radical scavenging assays.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on schisanalactone A.